Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Rabin

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
World Education Reports|January 1, 1973
The forumK Rabin
Indian Journal of Dental Research : Official Publication of Indian Society for Dental Research|June 10, 2006
Correction of anterior open bite in a case of achondroplasiaS Karpagam, K Rabin, Mathew George, et al.
Psychiatric Rehabilitation Journal|January 5, 2002
Improving accessibility: the experience of a Canadian Mental Health AgencyJ Pyke, L Morris, K Rabin, et al.
Journal of the National Cancer Institute|November 16, 1994
High frequency of germline p53 mutations in childhood adrenocortical cancerJ Wagner, C Portwine, K Rabin, et al.
Leukemia|November 23, 2016
Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathwayY Shen, C S Park, K Suppipat, et al.
Journal of Bone Oncology|June 22, 2019
Unplanned admissions for patients with myeloma in the UK: Low frequency but high costsSpyros Kolovos, Guido Nador, Bhuvan Kishore, et al.
Frontiers in Oncology|August 9, 2021
Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple MyelomaCatherine S Y Lecat, Jessica B Taube, William Wilson, et al.
Frontiers in Oncology|October 17, 2025
Current quality of life questionnaires are not relevant for assessing QOL issues in multiple myeloma patients in the era of modern therapies: results from a survey with myeloma patients and myeloma healthcare professionalsCatherine S Y Lecat, Sotirios Bristogiannis, Dipal Mehta, et al.
Haematologica|April 29, 2021
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>)Kwee L Yong, Samantha Hinsley, Holger W Auner, et al.
Bone Marrow Transplantation|May 10, 2023
An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMTMeral Beksac, Simona Iacobelli, Linda Koster, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
World Education Reports|January 1, 1973
The forumK Rabin
Indian Journal of Dental Research : Official Publication of Indian Society for Dental Research|June 10, 2006
Correction of anterior open bite in a case of achondroplasiaS Karpagam, K Rabin, Mathew George, et al.
Psychiatric Rehabilitation Journal|January 5, 2002
Improving accessibility: the experience of a Canadian Mental Health AgencyJ Pyke, L Morris, K Rabin, et al.
Journal of the National Cancer Institute|November 16, 1994
High frequency of germline p53 mutations in childhood adrenocortical cancerJ Wagner, C Portwine, K Rabin, et al.
Leukemia|November 23, 2016
Inactivation of KLF4 promotes T-cell acute lymphoblastic leukemia and activates the MAP2K7 pathwayY Shen, C S Park, K Suppipat, et al.
Journal of Bone Oncology|June 22, 2019
Unplanned admissions for patients with myeloma in the UK: Low frequency but high costsSpyros Kolovos, Guido Nador, Bhuvan Kishore, et al.
Frontiers in Oncology|August 9, 2021
Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple MyelomaCatherine S Y Lecat, Jessica B Taube, William Wilson, et al.
Frontiers in Oncology|October 17, 2025
Current quality of life questionnaires are not relevant for assessing QOL issues in multiple myeloma patients in the era of modern therapies: results from a survey with myeloma patients and myeloma healthcare professionalsCatherine S Y Lecat, Sotirios Bristogiannis, Dipal Mehta, et al.
Haematologica|April 29, 2021
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK<i>five</i>)Kwee L Yong, Samantha Hinsley, Holger W Auner, et al.
Bone Marrow Transplantation|May 10, 2023
An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMTMeral Beksac, Simona Iacobelli, Linda Koster, et al.
Pageof 2